Would-be entrants to the embryonic stem-cell business find access to the technology prohibitively expensive, Meredith Wadman reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Licensing fees slow advance of stem cells. Nature 435, 272–273 (2005). https://doi.org/10.1038/435272a
Published:
Issue Date:
DOI: https://doi.org/10.1038/435272a
This article is cited by
-
Research sharing, ethics and public benefit
Nature Biotechnology (2007)
-
The global stem cell patent landscape: implications for efficient technology transfer and commercial development
Nature Biotechnology (2007)
-
Patenting the obvious?
Nature (2007)
-
Leaders and laggards in the stem cell enterprise
Nature Biotechnology (2005)
-
The gatekeepers of hES cell products
Nature Biotechnology (2005)